USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ROCKLAND IMMUNOCHEMICALS, INC.
Address:
650 ENGLESVILLE ROAD
BOYERTOWN, PA 19512-
Phone:
N/A
URL:
N/A
EIN:
131986244
DUNS:
058999129
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,015,038.00 4

Award List:

Novel Point-of-Care Multiplex Lyme Disease Test

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$315,172.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Lyme disease (LD) is caused by spirochetal bacteria from the genus Borrelia. Borrelia burgdorferi is the predominant cause of Lyme disease in the United States, whereas Borrelia afzelii and Borrelia garinii are implicat ed in most European cases. CDC reported… More

MULTIPLEXED ASSAYS FOR AKT/M TOR PATHWAY - PHASE I SBIR TOPIC

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$149,937.00
Agency:
HHS
Principal Investigator:
Hiep Tran – (800) 656-7625
Abstract:
PTEN/Akt/mTORC 1and2 signal pathway is a critical regulator of cell survival, cell growth and proliferation, angiogenesis, cellular metabolism, cell migration and invasion and glucose uptake. A number of anticancer drugs in clinical trials are targeting this pathway. In Phase I, we will develop… More

Not Available

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$299,954.00
Agency:
HHS
Principal Investigator:
Hiep Tran
Abstract:
Antibody therapy offers treatment for a wide range of diseases and can extend the life of cancer patients, but the treatment cost is extremely expensive. as patent protection of some current antibodies will expire in coming years, there is an opportunity to develop generic and lower priced versions… More

TOPIC 324 PHASE I 9 MONTH FUNDING; NOVEL IMAGING AGENTS T EXPAND TE CLINICAL TOOL

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$249,975.00
Agency:
HHS
Principal Investigator:
Carl Ascoli – 800-656-7625
Abstract:
Medical imaging and targeted therapy are the central components in the clinical management of cancer patients. Rockland Immunochemicals, Inc. is teaming up with Abzyme Therapeutics LLC to develop novel imaging agents that can be used in both cancer diagnosis and targeted therapy. In this phase I… More